Bioengineered Tissue Program

About iOrganBio

iOrganBio is an early-stage, private biotech focused on creating implantable, bioengineered organ replacements to solve the organ transplant crisis. The company leverages a proprietary platform integrating patient-derived stem cells, 3D bioprinting of biocompatible scaffolds, and advanced tissue maturation processes. While still in pre-clinical development, its technology holds transformative potential for treating end-stage organ failure. The company is likely pre-revenue and backed by venture capital, operating in a high-risk, high-reward segment of the regenerative medicine field.

Therapeutic Areas

Other Organ Failure / Transplantation Drugs